Protagonist Therapeutics, Inc (PTGX) Scorecard
- 2026-Q2: Total return Win; Revenue growth Win; EPS growth Lose.
- 2026-Q1: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q3: Total return Win; Revenue growth Lose; EPS growth Lose.
35/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 5 wins, 7 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q22/3 |
WinPTGX / S&P 16.30% / 15.20% |
WinPTGX / S&P 34.81% / 15.00% |
LosePTGX / S&P 39.73% / 50.40% |
| 2026-Q11/3 |
WinPTGX / S&P 20.68% / -4.33% |
LosePTGX / S&P -64.36% / 11.30% |
LosePTGX / S&P -333.33% / 27.70% |
| 2025-Q41/3 |
WinPTGX / S&P 31.48% / 2.65% |
LosePTGX / S&P -89.41% / 9.00% |
LosePTGX / S&P -148.70% / 13.40% |
| 2025-Q31/3 |
WinPTGX / S&P 20.19% / 8.12% |
LosePTGX / S&P -35.39% / 4.61% |
LosePTGX / S&P -76.28% / 13.45% |
| 2025-Q21/3 |
WinPTGX / S&P 14.29% / 10.94% |
LosePTGX / S&P -34.45% / 4.83% |
LosePTGX / S&P -72.96% / 10.63% |
| 2025-Q11/3 |
WinPTGX / S&P 25.28% / -4.27% |
LosePTGX / S&P -34.02% / 4.98% |
LosePTGX / S&P -69.05% / 10.57% |
| 2024-Q41/3 |
LosePTGX / S&P -14.22% / 2.41% |
WinPTGX / S&P 624.05% / 5.25% |
LosePTGX / S&P -400.00% / 6.15% |
| 2024-Q31/3 |
WinPTGX / S&P 29.87% / 5.89% |
LosePTGX / S&P PTGX unavailable / 5.89% |
LosePTGX / S&P -204.18% / 6.11% |
| 2024-Q21/3 |
WinPTGX / S&P 19.77% / 4.28% |
LosePTGX / S&P PTGX unavailable / 5.38% |
LosePTGX / S&P -200.37% / 5.12% |
| 2024-Q12/3 |
WinPTGX / S&P 26.17% / 10.56% |
WinPTGX / S&P 36565.08% / 5.71% |
LosePTGX / S&P -188.42% / 5.59% |
| 2023-Q42/3 |
WinPTGX / S&P 37.47% / 11.69% |
WinPTGX / S&P 125.73% / 6.81% |
LosePTGX / S&P -45.98% / 7.78% |
| 2023-Q31/3 |
LosePTGX / S&P -39.61% / -3.27% |
LosePTGX / S&P -100.00% / 7.52% |
WinPTGX / S&P -1.87% / -5.03% |
| 2023-Q22/3 |
WinPTGX / S&P 20.09% / 8.74% |
LosePTGX / S&P -100.00% / 9.50% |
WinPTGX / S&P -1.82% / -8.57% |
| 2023-Q12/3 |
WinPTGX / S&P 110.82% / 7.50% |
LosePTGX / S&P -98.17% / 10.77% |
WinPTGX / S&P 10.04% / -15.69% |
| 2022-Q42/3 |
WinPTGX / S&P 29.42% / 7.56% |
LosePTGX / S&P -2.84% / 11.88% |
WinPTGX / S&P -3.33% / -17.99% |
| 2022-Q32/3 |
WinPTGX / S&P 6.57% / -4.88% |
WinPTGX / S&P 44.31% / 13.47% |
LosePTGX / S&P PTGX unavailable / -1.41% |
| 2022-Q21/3 |
LosePTGX / S&P -66.60% / -16.10% |
WinPTGX / S&P 67.11% / 13.71% |
LosePTGX / S&P PTGX unavailable / 11.04% |
| 2022-Q10/3 |
LosePTGX / S&P -30.76% / -4.60% |
LosePTGX / S&P PTGX unavailable / 15.97% |
LosePTGX / S&P PTGX unavailable / 42.23% |
| 2021-Q41/3 |
WinPTGX / S&P 93.00% / 11.03% |
LosePTGX / S&P PTGX unavailable / 15.00% |
LosePTGX / S&P PTGX unavailable / 96.40% |
| 2021-Q30/3 |
LosePTGX / S&P -60.52% / 0.58% |
LosePTGX / S&P PTGX unavailable / 10.77% |
LosePTGX / S&P PTGX unavailable / 69.42% |
| 2021-Q21/3 |
WinPTGX / S&P 73.28% / 8.55% |
LosePTGX / S&P PTGX unavailable / 6.58% |
LosePTGX / S&P PTGX unavailable / 51.81% |
| 2021-Q11/3 |
WinPTGX / S&P 28.47% / 6.17% |
LosePTGX / S&P PTGX unavailable / -1.06% |
LosePTGX / S&P PTGX unavailable / 7.39% |
| 2020-Q40/3 |
LosePTGX / S&P 3.12% / 12.15% |
LosePTGX / S&P PTGX unavailable / -3.72% |
LosePTGX / S&P PTGX unavailable / -33.42% |
| 2020-Q31/3 |
WinPTGX / S&P 10.70% / 8.93% |
LosePTGX / S&P PTGX unavailable / -2.04% |
LosePTGX / S&P PTGX unavailable / -27.10% |
| 2020-Q21/3 |
WinPTGX / S&P 150.14% / 20.54% |
LosePTGX / S&P PTGX unavailable / -0.46% |
LosePTGX / S&P PTGX unavailable / -27.11% |
| 2020-Q11/3 |
WinPTGX / S&P 0.14% / -19.60% |
LosePTGX / S&P PTGX unavailable / 3.47% |
LosePTGX / S&P PTGX unavailable / -14.75% |
| 2019-Q40/3 |
LosePTGX / S&P -41.30% / 9.07% |
LosePTGX / S&P PTGX unavailable / 5.36% |
LosePTGX / S&P PTGX unavailable / 2.99% |
| 2019-Q30/3 |
LosePTGX / S&P -0.83% / 1.70% |
LosePTGX / S&P PTGX unavailable / 5.02% |
LosePTGX / S&P PTGX unavailable / 0.21% |
| 2019-Q20/3 |
LosePTGX / S&P -3.66% / 4.30% |
LosePTGX / S&P PTGX unavailable / 6.64% |
LosePTGX / S&P PTGX unavailable / 8.65% |
| 2019-Q11/3 |
WinPTGX / S&P 86.78% / 13.65% |
LosePTGX / S&P PTGX unavailable / 8.12% |
LosePTGX / S&P PTGX unavailable / 14.29% |
| 2018-Q40/3 |
LosePTGX / S&P -34.60% / -13.52% |
LosePTGX / S&P PTGX unavailable / 9.05% |
LosePTGX / S&P PTGX unavailable / 18.23% |
| 2018-Q31/3 |
WinPTGX / S&P 53.13% / 7.71% |
LosePTGX / S&P PTGX unavailable / 10.21% |
LosePTGX / S&P PTGX unavailable / 19.06% |
| 2018-Q20/3 |
LosePTGX / S&P -21.77% / 3.43% |
LosePTGX / S&P PTGX unavailable / 9.03% |
LosePTGX / S&P PTGX unavailable / 14.46% |
| 2018-Q10/3 |
LosePTGX / S&P -58.70% / -0.76% |
LosePTGX / S&P PTGX unavailable / 7.68% |
LosePTGX / S&P PTGX unavailable / 12.46% |
| 2017-Q41/3 |
WinPTGX / S&P 17.71% / 6.64% |
LosePTGX / S&P PTGX unavailable / 7.03% |
LosePTGX / S&P PTGX unavailable / 13.82% |
| 2017-Q31/3 |
WinPTGX / S&P 56.23% / 4.48% |
LosePTGX / S&P PTGX unavailable / 5.68% |
LosePTGX / S&P PTGX unavailable / 17.57% |
| 2017-Q20/3 |
LosePTGX / S&P -11.71% / 3.09% |
LosePTGX / S&P PTGX unavailable / 4.83% |
LosePTGX / S&P PTGX unavailable / 17.74% |
| 2017-Q10/3 |
LosePTGX / S&P -41.75% / 6.07% |
LosePTGX / S&P PTGX unavailable / 3.67% |
LosePTGX / S&P PTGX unavailable / 13.32% |
| 2016-Q41/3 |
WinPTGX / S&P 4.07% / 3.82% |
LosePTGX / S&P PTGX unavailable / 2.09% |
LosePTGX / S&P PTGX unavailable / 7.05% |
| 2016-Q30/3 |
LosePTGX / S&P PTGX unavailable / 3.85% |
LosePTGX / S&P PTGX unavailable / 0.20% |
LosePTGX / S&P PTGX unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | PTGX total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 153.18% | 20.78% |
| Annualized return | 153.18% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | PTGX total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 200.87% | 83.14% |
| Annualized return | 24.64% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | PTGX total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 1136.56% | 319.30% |
| Annualized return | 28.59% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |